

## **CS Pharmaceuticals announces appointment of John Dawson CBE as Non Executive Director**

London, England, June 1, 2022, CS Pharmaceuticals Ltd. (CSP), a British speciality pharmaceutical company focused on first- and best-in-class speciality therapeutics and treatments for rare diseases in China, are pleased to announce the appointment of John Dawson CBE as Non Executive Director.

John Dawson CBE, joined Oxford Biomedica's Board as a Non-Executive Director in August 2008, and was appointed Chief Executive Officer from October 2008 until January 2022. Prior to this he held senior management positions in the European operations of Cephalon Inc., including Chief Financial Officer and Head of Business Development Europe. While at Cephalon he led many deals building the European business to over 1,000 people and to a turnover of several hundred million US dollars. "We are hugely excited to welcome John Dawson to the Board", said Darren Mercer CEO of CSP. "John's rich experience and deep insights into building businesses and creating innovative deal structures will be of significant value to CSP as we raise capital and transact with international pharmaceutical companies to bring innovative and differentiated pharmaceutical products into China."

"I am delighted to be joining CSP at this stage in the business", said John Dawson. "The Team that CSP have assembled, the licensing transactions they have been able to complete in a short period of time, coupled with the recent reforms to the pharmaceutical industry that have occurred in China combine to make CSP's vision of becoming the partner of choice for Western pharmaceutical companies in China a vibrant reality."

### **About CS Pharmaceuticals**

CS Pharmaceuticals (CSP) is a British multinational pharmaceutical company focused on licensing Chinese commercialisation rights to Western rare disease and speciality medicines. The company, with its headquarters in London and offices in Beijing and Shanghai, offers dedicated regulatory, market access, medical and commercial expertise, in addition to international-standard compliance and legal capabilities. The team has an impressive track record of success in China, providing partners with significant experience in this fast-growing market. With its dedicated commercialisation platform, CSP is rapidly becoming a 'go-to' trusted licensing partner, expanding its portfolio of innovative rare disease and ophthalmology assets while making business easier for companies wishing to develop and commercialize their products in China.

[www.cspharmaceuticals.com](http://www.cspharmaceuticals.com)

### **Contacts**

CS Pharmaceuticals  
Darren Mercer, Chief Executive Officer

Tel: +44 (0) 2037 534691